Trial Profile
A Multicenter, Open-Label Study of Sebelipase Alfa in Patients With Lysosomal Acid Lipase Deficiency
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Sebelipase alfa (Primary)
- Indications Cholesterol ester storage disease
- Focus Adverse reactions
- Sponsors Alexion AstraZeneca Rare Disease; Alexion Pharmaceuticals; Synageva BioPharma
- 14 Feb 2018 Status changed from active, no longer recruiting to completed.
- 09 Feb 2018 This trial has been completed in Belgium(2017-12-28).
- 26 Jan 2018 This trial has been completed in Denmark (2017-12-28).